Thanks. Not sure how to check on that, but I guess because of that poor reputation, the stock is languishing where it is today. I'm hoping if is finally turning the corner. Evidently it had been as high as $100 in the past.
It looks like they have funding now through Q1 or 2 of 2018 so that is a good thing and in that timeframe, they have some trial data coming in which will help them then make decisions as to what to pursue with the funds they have.
They could go with what they have been doing, or they could switch gears and further pursue the oncology direction through the company they just merged with.
If they do that, they would probably sell off some of their current assets to help fund that so hopefully they will not have to resort to that kind of toxic financing in the future.
News 
Market Data 
Discover 
